

Association Between Population-Level Factors and Household Secondary Attack Rate of SARS-CoV-2: A Systematic Review and Meta-analysis

Can Wang,¹ Xiaotong Huang,¹ Eric H. Y. Lau,^{1,2} Benjamin J. Cowling,^{1,2} and Tim K. Tsang^{1,2}

¹WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China, and ²Laboratory of Data Discovery for Health Limited, Hong Kong Science and Technology Park, New Territories, Hong Kong Special Administrative Region, China

Background. Accurate estimation of household secondary attack rate (SAR) is crucial to understand the transmissibility of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The impact of population-level factors, such as transmission intensity in the community, on SAR estimates is rarely explored.

Methods. In this study, we included articles with original data to compute the household SAR. To determine the impact of transmission intensity in the community on household SAR estimates, we explored the association between SAR estimates and the incidence rate of cases by country during the study period.

Results. We identified 163 studies to extract data on SARs from 326 031 cases and 2 009 859 household contacts. The correlation between the incidence rate of cases during the study period and SAR estimates was 0.37 (95% CI, 0.24–0.49). We found that doubling the incidence rate of cases during the study period was associated with a 1.2% (95% CI, 0.5%–1.8%) higher household SAR.

Conclusions. Our findings suggest that the incidence rate of cases during the study period is associated with higher SAR. Ignoring this factor may overestimate SARs, especially for regions with high incidences, which further impacts control policies and epidemiological characterization of emerging variants.

Keywords. SARS-CoV-2; heterogeneity; population incidence; secondary attack rate.

Studying household transmission is important to evaluating the transmissibility of an emerging or re-emerging virus [1, 2]. Household secondary attack rate (SAR), which is used to characterize the risk and heterogeneity in the risk of transmission, has been broadly reported for coronavirus disease 2019 (COVID-19) [3–5]. Furthermore, the household is one of the most important settings for transmission of infectious diseases, including influenza and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [2, 6]. Therefore, understanding household transmission dynamics of SARS-CoV-2 would provide valuable information to guide control policies.

Previous reviews on household transmission studies have suggested that household SAR estimates (hereafter referred to as household SAR unless otherwise specified) could be different

due to emerging variants, study location, and period [3, 7]. A range of characteristics of household members that may impact SAR estimates has been proposed, including age of index cases and contacts, symptom status of index cases and contacts, and comorbidities of contacts [3, 4, 8]. However, other population-level factors including population immunity, mobility change, and the intensity of community transmission may impact SAR estimates. These unaccounted-for population-level factors are also commonly acknowledged as limitations in the work of evaluating epidemiology and transmission risk of SARS-CoV-2, as well as making public health decisions [3, 4, 9]. Here, we aim to systematically review and analyze published data from household transmission studies to characterize the epidemiological and population-level factors affecting household SAR estimates.

METHODS

Definition of Household Secondary Attack Rate

In this study, an index case was defined as the first detected case in a household, while secondary cases were defined as the identified infected household contacts of the index case. The secondary attack rate within a household or family was defined as the proportion of infected household/family contacts. Household or family contacts include those living in the same residence as the index/primary case and family members of the index/primary case.

Received 02 September 2022; editorial decision 09 December 2022; accepted 14 December 2022; published online 16 December 2022

Correspondence: Tim K. Tsang, PhD, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, 7 Sassoon Road, Pokfulam, Hong Kong Special Administrative Region, China (timtsang@connect.hku.hk).

Open Forum Infectious Diseases®

© The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (<https://creativecommons.org/licenses/by-nc-nd/4.0/>), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

<https://doi.org/10.1093/ofid/ofac676>

Search Strategy and Selection Criteria

This systematic review was conducted following the updated Preferred Reporting Items for Systematic Review and Meta-analysis (PRISMA) statement [10]. A standardized search was done in PubMed, using search terms including “SARS-CoV-2,” “COVID-19,” “secondary attack rate,” “household,” “family transmission,” or “close contacts” (Supplementary Data 1). Articles published before March 9, 2022, were identified from previous systematic reviews using the same search terms [3, 7]. Then we used the same search terms to identify articles published from March 9 to June 9, 2022. There were no restrictions on language or study location. Additional relevant articles from reference sections were also reviewed.

Two authors (C.W. and X.H.) independently screened the titles and full texts and extracted data from the included studies, with disagreement resolved by consensus together with a third author (T.K.T.). Studies identified from different sources were de-duplicated. We included studies that provided sufficient data for computing the empirical SAR. The following articles were excluded: (1) case reports or case series focusing on an individual household; (2) full text was not available.

Data were extracted from included studies into a standard form (Supplementary Table 3), including the following information: (1) study period, (2) study locations, (3) the number of infections among household contacts, (4) the number of all identified household contacts, (5) ascertainment method for infections (types of laboratory tests or symptom-based ascertainment), (6) test coverage among identified contacts, (7) predominant circulating viruses during the study period (ancestral strains or variants), and (8) precision of study period (days or months). When exact days were not available, we assumed the day was the 15th. To explore the relationship between household SAR estimates and preexisting population immunity or incidence rate of cases in a population during the study period, we obtained data on the population size, time series of number of COVID-19 cases and deaths, and the number of people fully vaccinated by countries from the Our World in Data and World Health Organization databases [11, 12].

Data Analysis

As most studies did not report variant-specific SAR, we grouped predominant circulating viruses during each study period into the following 4 categories (Supplementary Data 2): (1) ancestral strains, (2) any variants (except Omicron) with ancestral strains, (3) any variants (except Omicron) without ancestral strains, (4) Omicron. We obtained information on predominant circulating viruses during the study period from the Nextstrain website if such information was not available in the study [13]. When determining circulating viruses during the study period, we only included those dominant strains that accounted for >10% of all identified viruses.

For each study, we extracted the number of infections and household contacts during the study period, SAR estimates, and corresponding 95% CIs. Then, we conducted random-effects meta-analyses using the inverse variance method and restricted maximum likelihood estimator for heterogeneity to summarize SAR estimates for studies with different viruses, case ascertainment methods, or study periods [14, 15]. The Cochran Q test and the I^2 statistic were used to identify and quantify heterogeneity among included studies [16]. An I^2 value >75% indicated high heterogeneity [16]. A meta-analysis was conducted by the circulating viruses, test coverage, only polymerase chain reaction (PCR), or other case ascertainment methods for cases in households, as well as whether the study period was before June 1, 2020, to explore the impact of insufficient tests during the early pandemic period.

We explored differences in SAR estimates by predominant circulating viruses (hereafter referred to as the baseline model), as multiple reports suggested that the transmissibility of certain strains and variants could be different. To evaluate the impact of preexisting population immunity or incidence rate of cases in the population on SAR estimates, we adapted a meta-regression approach. Based on the location of each study, we computed the \log_2 -transformed cumulative incidence of cases on the day before the beginning of the study. We also used cumulative incidence of deaths as an alternative measure since reporting of death was more stable and less sensitive to reporting bias [17]. In addition, we explored the effects of preexisting population immunity, reflected by the proportion of people fully vaccinated before the start of the study, on SAR estimates. Finally, as a proxy of intensity of transmission in the community, the \log_2 -transformed incidence rate of cases or deaths during the study period was also computed to evaluate its impact on SAR estimates using the same meta-regression approach. In these analyses, SARs were adjusted by predominant circulating viruses since the SARs for different viruses could be different. We conducted a sensitivity analysis by repeating the same analysis but restricted to studies with accurate study periods. Statistical analyses were conducted using R, version 4.0.5 (R Foundation for Statistical Computing, Vienna, Austria).

RESULTS

In the systematic review, we updated the search from Madewell et al. [7] and identified 579 new studies with 2 duplicates. After screening the titles and abstracts of the remaining articles, we screened 111 full texts. On the basis of our selection criteria, we excluded 88 of those studies, and 23 met our inclusion criteria (Supplementary Table 1) [18–40]. Combined with 140 studies identified from previous reviews [5, 41–166], there were 163 studies included in our analysis (Supplementary Figure 1, Supplementary Table 2). Overall, 163 studies provided 179 estimates of household SAR, with 326 031 cases among 2 009 859

household contacts (Figure 1). Among all included studies, 127 provided accurate study periods. Regarding case ascertainment methods among household contacts, almost all studies used PCR, while 29 studies additionally used symptoms, antigen, serology, or clinical criteria. Ten study used rapid tests [167–169], serology [19], antigen [169–171], or symptoms [172–174] instead of PCR. Four remaining studies had unknown ascertainment methods for secondary cases [175–178]. Regarding test coverage of household contacts, most studies (118 out of 163) tested all identified household contacts, while other studies provided test coverages ranging from 11% to 96% or only symptomatic individuals were tested. The remaining 15 studies did not provide information on test coverage among identified contacts. In terms of predominant circulating viruses, 60 estimates were based on cases infected by ancestral strains only, while the remaining 72, 38, and 9 estimates investigated infections by any variants (except Omicron) with ancestral strains, any variants (except Omicron) without ancestral strains, and Omicron, respectively.

Impact of Population-Level Incidence Rate of Cases During the Study Period and Cumulative Incidence of Cases Before the Study Period on Household SAR

Despite large heterogeneity in SAR estimates, we still observed a positive trend between the SAR and the incidence rate of cases (correlation, 0.37; 95% CI, 0.24–0.49; $P < .01$) or deaths (correlation, 0.34; 95% CI, 0.20–0.47; $P < .01$) (Figure 2). After accounting for predominant circulating viruses during the study period in the meta-regression, we found that doubling the incidence rate of cases and deaths during the study period was associated with 1.2% (95% CI, 0.5%–1.8%) and 1.3% (95% CI, 0.6%–1.9%) higher SAR (Table 1). In addition, we estimated that doubling the cumulative incidence of cases and deaths during the study period was related to 0.9% (95% CI, 0.5%–1.2%) and 1% (95% CI, 0.5%–1.4%) higher SAR, respectively. For studies that provided accurate study periods, we observed similar directions and magnitudes for the above factors.

Impact of Predominant Circulating Viruses and Epidemiological Factors

The SAR estimates ranged from 0.5% to 73.8% (Figure 3). These estimates varied substantially for different variants, study periods (before or after June 1, 2020), test coverages (whether all identified household contacts were tested), and case ascertainment methods (Figure 4; Supplementary Figure 2). The SARs for the Omicron variant were the highest among all virus categories (37.5%; 95% CI, 28.3%–46.7%), followed by any variants (except Omicron) with ancestral strains (30.3%; 95% CI, 26.4%–34.3%) and any variants (except Omicron) without ancestral strains (28.2%; 95% CI, 24.8%–31.7%), while the lowest estimate for ancestral strains only was 19.5% (95% CI, 15.9%–23.1%). Regarding the test coverage, we found that household SAR estimates for studies that tested all identified household




Figure 1. Estimates of household SAR for all studies grouped by circulating viruses during the study period. Dashed vertical lines represent 0%, 30%, 60%, and 90% household SAR estimates. Abbreviation: SAR, secondary attack rate.




Figure 2. Household SAR estimates vs incidence rates of cases and deaths during the study period. *A*, Household SAR estimates vs the incidence rate of cases (per 1 000 000) during the study period (in log scale) by country. *B*, Household SAR estimates vs the incidence rate of deaths (per 100 000 000) during the study period (in log scale) by country. Results of Spearman correlation tests are provided (r). Only studies with positive incidence rates (in log scale) were selected to present the figures. Abbreviation: SAR, secondary attack rate.

contacts (27.5%; 95% CI, 24.9%–30.1%) were higher than for studies that did not conduct universal testing (22.5%; 95% CI, 18.7%–26.2%). For studies conducted before June 1, 2020, the household SAR estimate was 18.2% (95% CI, 15.4%–21.0%), which was significantly lower than the SAR derived from those conducted after June 1, 2020 (30.7%; 95% CI, 28.0%–33.5%). Finally, we detected a significantly lower household SAR (24.0%; 95% CI, 21.5%–26.4%) for studies that only used PCR for case ascertainment of secondary cases than those not (32.6%; 95% CI, 28.2%–37.0%). Restricting to estimates from studies with accurate study periods, we observed similar patterns and magnitudes regarding the above factors (Figure 3).

Based on meta-regression (Table 1), we found that compared with ancestral strains only, the SARs for any variants (except Omicron) with ancestral strains, any variants (except Omicron) without ancestral strains, or Omicron were 8.7% (95% CI, 3.8%–13.6%), 11.0% (95% CI, 5.2%–16.8%), and 18.0% (95% CI, 7.9%–28.1%) higher, respectively. The results were similar if only considering studies with accurate study periods. We found no association between the proportion of people fully vaccinated with primary doses in the population before the study period and SARs. Regarding the study period, we found that having a study period before June 1, 2020, was associated with a lower SAR after accounting for predominant circulating viruses, with –9.8% (95% CI, –15.4% to –4.1%) and –9.8% (95% CI, –16.3% to –3.4%) for all studies and studies with accurate study periods, respectively. We found that all secondary cases ascertained by PCR only was associated with a 6.6% (95% CI, 1.8%–11.3%) lower SAR vs using other

ascertainment methods. Finally, testing all household members was associated with a 7.0% (95% CI, 1.2%–12.7%) higher SAR, restricting to studies with accurate study periods.

DISCUSSION

Accurate estimation of household SAR was crucial, as the household is one of the most important settings for transmission of many viruses including SARS-CoV-2 [6, 8]. Furthermore, household SAR was an important measure to determine the transmission potential of emerging viruses [2]. In this study, we synthesized SAR estimates from household transmission studies of SARS-CoV-2. We found that there was considerable heterogeneity in SAR estimates, and several factors may have impacts on SARs, which may have impacts on both public health decisions and scientific implications.

We found that a higher population-level incidence rate of cases or deaths during the study period was associated with higher SAR estimates. The SAR estimates did not account for the source of infection for secondary cases [2], and therefore some secondary cases may have been infected from the community rather than index cases within households. Our findings suggest that SAR estimates may be correlated with the community incidence rate, and therefore it might be possible to monitor the household SAR to determine the transmission intensity in communities. On the other hand, this finding could be a confounding result induced by other factors. For example, it may be explained by more advanced diagnostic or detection tools and testing frequencies for COVID-19 in some countries,

Table 1. Association Between Household SAR Estimates and Epidemiological and Population-Level Factors

Outcome	SAR (All Studies), %	SAR (Studies With Accurate Study Period), %
Baseline model: adjusted for SARS-CoV-2 variants		
Circulating virus		
Ancestral strains	Ref	...
Any variants (except Omicron) with ancestral strains	8.7 (3.8 to 13.6) ^a	7.0 (1.6 to 12.4) ^a
Any variants (except Omicron) without ancestral strains	11.0 (5.2 to 16.8) ^a	10.6 (4.0 to 17.2) ^a
Omicron	18.0 (7.9 to 28.1) ^a	12.1 (0.09 to 24.1) ^a
Model 1: Baseline model with incidence rate of cases/deaths during the study period		
Incidence rate of cases in log ₂ scale	1.2 (0.5 to 1.8) ^a	1.1 (0.4 to 1.8) ^a
Incidence rate of deaths in log ₂ scale	1.3 (0.6 to 1.9) ^a	1.2 (0.4 to 2.0) ^a
Model 2: Baseline model with cumulative incidence of cases/deaths before the study period		
Cumulative incidence of cases in log ₂ scale	0.9 (0.5 to 1.2) ^a	0.8 (0.3 to 1.2) ^a
Cumulative incidence of death in log ₂ scale	1.0 (0.5 to 1.4) ^a	0.9 (0.4 to 1.3) ^a
Model 3: Baseline model with adjustment for the proportion of people fully vaccinated before the study period		
Proportion of people fully vaccinated	-9.3 (-25.9 to 7.3)	-17.7 (-36.3 to 0.9)
Model 4: Baseline model with adjustment for epidemiological factors		
All household contacts were tested	4.8 (-0.2 to 9.8)	7.0 (1.2 to 12.7) ^a
Early period (before 2020-06-01)	-9.8 (-15.4 to -4.1)	-9.8 (-16.3 to -3.4) ^a
Ascertainment only by PCR for secondary cases	-6.6 (-11.3 to -1.8) ^a	-4.7 (-1.3 to 0.9)

Abbreviations: PCR, polymerase chain reaction; SAR, secondary attack rate; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.

^aStatistically significant (*P* < .05).




Figure 3. Pooled estimates of household SARs stratified by circulating viruses, study period, test coverage, and case ascertainment methods, with results of a sensitivity analysis restricting to studies with accurate study periods. Abbreviations: PCR, polymerase chain reaction; SAR, secondary attack rate.

and therefore both the population-level incidence and household SAR were higher. Also, less stringent public health and social measures (PHSMs) and lower levels of maintenance of good hygiene in countries may also contribute to higher incidence rates of cases. Household SAR by index cases' characteristics has been used to evaluate factors affecting infectiousness [8], and our results suggest that such an approach may be

biased as SAR estimates did not account for the source of infection.

We also found that higher cumulative incidence of cases or deaths before the study was associated with higher SAR. This may be explained by the fact that there were repeated and denser exposures within households compared with in communities [8], and therefore transmission in countries with higher




Figure 4. Distributions and pooled estimates of household SARs. *A*, By circulating virus. *B*, By study period. *C*, By test coverage of identified household contacts and *D*, By case ascertainment methods for secondary cases. Black dots are point estimates from meta analysis with bars representing 95% CIs. Abbreviations: PCR, polymerase chain reaction; SAR, secondary attack rate.

population immunity may be shifted from community settings to households. However, this may also be a confounding result caused by higher testing frequencies, better diagnostic or detection tools, or lower risk perceptions toward COVID-19 at the country level [179–182].

In addition, we found that SAR estimates vary substantially by the study period, predominant circulating viruses, and epidemiological factors including testing coverage and case ascertainment method [3, 7]. We found that the SARs for Omicron and other variants were higher than ancestral strains, consistent with previous reviews and modeling studies for estimating

transmissibility of emerging variants [7, 52, 183, 184]. After accounting for differences in household SAR estimates by circulating viruses, we still detected a significantly higher SAR for studies conducted after June 1, 2020, potentially due to the improvement of detection or diagnostic approaches and relaxation of PHSMs. Similarly, we also found that testing all identified household contacts and using only PCR for case ascertainment for both index and secondary cases were associated with higher household SAR, indicating that such differences in testing or screening strategies contributed to the substantial heterogeneity of SAR estimates. We found that the proportion

of people fully vaccinated with primary doses was not associated with SAR, despite a negative point estimate. There could be large variations due to different vaccine types, effectiveness, and the waning effect of immunity induced by vaccination.

Our study is subject to several limitations. First, we included studies with family contacts who live outside the household of the index case. However, it is not likely that this was a significant factor contributing to the heterogeneity in household SAR as a previous study found that the SAR for household contacts was not significantly different from that for family contacts [4]. Second, there was a lack of detailed or accurate data on determining the study period and circulating viruses for some studies. Although we assumed a midday and obtained dominant viruses for those studies with missing information, data from the Nexstrain website may have uncertainties surrounding estimates of specific transmission dates [13, 185]. Still, our results were broadly consistent in a sensitivity analysis only including studies with accurate study periods. Finally, we did not consider within-household factors associated with household transmission that have been reported previously, such as age and sex of household members, symptom status of index cases, and household crowding, etc., as this individual-level information may not be publicly available [3, 8].

In conclusion, our findings suggested that population-level factors including the incidence rate in a country during the study period and testing strategies contributed to the high SAR estimates. Therefore, ignoring these factors could lead to inaccurate or even biased estimates of transmissibility. This may have impacts on informing control policies and epidemiological characterization of emerging viruses or variants.

Supplementary Data

Supplementary materials are available at *Open Forum Infectious Diseases* online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.

Acknowledgments

The authors thank Julie Au for technical assistance.

Financial support. This project was supported by the Health and Medical Research Fund, Food and Health Bureau, Government of the Hong Kong Special Administrative Region and the Collaborative Research Fund (Project No. C7123–20G), and the general research fund (Project No. 17100822) of the Research Grants Council of the Hong Kong Special Administrative Region Government. B.J.C. is supported by the AIR@innoHK program of the Innovation and Technology Commission of the Hong Kong SAR Government. T.K.T. was supported by the Enhanced New Staff Start-up Research Grant from LKS Faculty of Medicine.

Potential conflicts of interest. B.J.C. consults for AstraZeneca, Fosun Pharma GlaxoSmithKline, Moderna, Pfizer Roche, and Sanofi Pasteur. All other authors: no reported conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

Patient consent. This study is a literature review and meta-analysis that does not include factors necessitating patient consent.

References

1. Pitzer VE, Cohen T. Household studies provide key insights on the transmission of, and susceptibility to, SARS-CoV-2. *Lancet Infect Dis* **2020**; 20:1103–4.
2. Tsang TK, Lau LLH, Cauchemez S, Cowling BJ. Household transmission of influenza virus. *Trends Microbiol* **2016**; 24:123–33.
3. Madewell ZJ, Yang Y, Longini IM Jr, Halloran ME, Dean NE. Factors associated with household transmission of SARS-CoV-2: an updated systematic review and meta-analysis. *JAMA Netw Open* **2021**; 4:e2122240.
4. Madewell ZJ, Yang Y, Longini IM Jr, Halloran ME, Dean NE. Household transmission of SARS-CoV-2: a systematic review and meta-analysis. *JAMA Netw Open* **2020**; 3:e2031756.
5. COVID-19 National Emergency Response Center, Epidemiology and Case Management Team, Korea Centers for Disease Control and Prevention. Coronavirus disease-19: summary of 2,370 contact investigations of the first 30 cases in the Republic of Korea. *Osong Public Health Res Perspect* **2020**; 11: 81–4.
6. Wong NS, Lee SS, Kwan TH, Yeoh EK. Settings of virus exposure and their implications in the propagation of transmission networks in a COVID-19 outbreak. *Lancet Reg Health West Pac* **2020**; 4:100052.
7. Madewell ZJ, Yang Y, Longini IM Jr, Halloran ME, Dean NE. Household secondary attack rates of SARS-CoV-2 by variant and vaccination status: an updated systematic review and meta-analysis. *JAMA Netw Open* **2022**; 5: e229317.
8. Thompson HA, Mousa A, Dighe A, et al. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) setting-specific transmission rates: a systematic review and meta-analysis. *Clin Infect Dis* **2021**; 73:e754–64.
9. Fung HF, Martinez L, Alarid-Escudero F, et al. The household secondary attack rate of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): a rapid review. *Clin Infect Dis* **2021**; 73(Suppl 2):S138–45.
10. Page MJ, McKenzie JE, Tetzlaff J, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ* **2021**; 372:n71.
11. World Health Organization. WHO coronavirus (COVID-19) dashboard. Available at: <https://covid19.who.int/data>. Accessed August 1, 2022.
12. Mathieu E, Ritchie H, Ortiz-Ospina E, et al. A global database of COVID-19 vaccinations. *Nat Hum Behav* **2021**; 5:947–53.
13. Nextstrain. Nextstrain SARS-CoV-2 resources. Available at: <https://nextstrain.org/sars-cov-2/>. Accessed June 10, 2022.
14. Veroniki AA, Jackson D, Bender R, et al. Methods to calculate uncertainty in the estimated overall effect size from a random-effects meta-analysis. *Res Synth Methods* **2019**; 10:23–43.
15. Thompson SG, Sharp SJ. Explaining heterogeneity in meta-analysis: a comparison of methods. *Stat Med* **1999**; 18:2693–708.
16. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *BMJ* **2003**; 327:557–60.
17. Lau H, Khosrawipour T, Kocbach P, Ichii H, Bania J, Khosrawipour V. Evaluating the massive underreporting and undertesting of COVID-19 cases in multiple global epicenters. *Pulmonology* **2021**; 27:110–5.
18. Alsvéd M, Nygren D, Thuresson S, Medstrand P, Fraenkel CJ, Löndahl J. SARS-CoV-2 in exhaled aerosol particles from COVID-19 cases and its association to household transmission. *Clin Infect Dis* **2022**; 75:e50–6.
19. Bhatt M, Plint AC, Tang K, et al. Household transmission of SARS-CoV-2 from unvaccinated asymptomatic and symptomatic household members with confirmed SARS-CoV-2 infection: an antibody-surveillance study. *CMAJ Open* **2022**; 10:E357–66.
20. Carvalho MS, Bastos LS, Fuller T, et al. Incidence of SARS-CoV-2 over four epidemic waves in a low-resource community in Rio de Janeiro, Brazil: a prospective cohort study. *Lancet Reg Health Am* **2022**; 12:100283.
21. Elgersma IH, Telle K, Elström P, Skagseth H, Kacelnik O. Transmission of severe acute respiratory coronavirus virus 2 (SARS-CoV-2) between hospital workers and members of their household: nationwide, registry-based, cohort study from Norway. *Infect Control Hosp Epidemiol* **2022**. doi: [10.1017/ice.2022.108](https://doi.org/10.1017/ice.2022.108).
22. Jørgensen SB, Nygård K, Kacelnik O, Telle K. Secondary attack rates for Omicron and Delta variants of SARS-CoV-2 in Norwegian households. *JAMA* **2022**; 327:1610–1.
23. Khan A, Mushtaq MH, Muhammad J, et al. Household COVID-19 secondary attack rate and associated determinants in Pakistan: a retrospective cohort study. *PLoS One* **2022**; 17:e0266277.
24. Kolodziej LM, van Lelyveld SFL, Haverkort ME, et al. High SARS-CoV-2 household transmission rates detected by dense saliva sampling. *Clin Infect Dis* **2022**; 75:e10–9.

25. Li D, Li AE, Li ZQ, et al. SARS-CoV-2 Delta variant in Jingmen City, Hubei province, China, 2021: children susceptible and vaccination breakthrough infection. *Front Microbiol* **2022**; 13:856757.
26. Ng OT, Koh V, Chiew CJ, et al. Impact of SARS-CoV-2 vaccination and paediatric age on Delta variant household transmission. *Clin Infect Dis* **2022**; 75: e35–43.
27. Ogata T, Tanaka H, Nozawa Y, et al. Increased secondary attack rate among unvaccinated household contacts of coronavirus disease 2019 patients with Delta variant in Japan. *Int J Environ Res Public Health* **2022**; 19:3889.
28. Satter SM, Bhuiyan TR, Abdullah Z, et al. Transmission of SARS-CoV-2 in the population living in high- and low-density gradient areas in Dhaka. *Bangladesh. Trop Med Infect Dis* **2022**; 7:53.
29. Schepers M, Zanger P, Jahn K, König J, Strauch K, Gianicolo E. Multi-household social gatherings contribute to the second SARS-CoV-2 wave in Rhineland-Palatinate, Germany, August to November 2020. *J Infect* **2022**; 84: 551–7.
30. Sordo AA, Dunn A, Gardiner ER, et al. Household transmission of COVID-19 in 2020 in New South Wales, Australia. *Commun Dis Intell* (2018) **2022**; 46.
31. Trobajo-Sanmartín C, Martínez-Baz I, Miqueleiz A, et al. Differences in transmission between SARS-CoV-2 Alpha (B.1.1.7) and Delta (B.1.617.2) variants. *Microbiol Spectr* **2022**; 10:e0000822.
32. Trunfio M, Richiardi L, Alladio F, et al. Determinants of SARS-CoV-2 contagiousness in household contacts of symptomatic adult index cases. *Front Microbiol* **2022**; 13:829393.
33. Tsang TK, Fang LQ, Zhang A, et al. Variability in transmission risk of SARS-CoV-2 in close contact settings: a contact tracing study in Shandong province, China. *Epidemics* **2022**; 39:100553.
34. Verberk JDM, de Hoog MLA, Westerhof I, et al. Transmission of SARS-CoV-2 within households: a remote prospective cohort study in European countries. *Eur J Epidemiol* **2022**; 37:549–61.
35. Zhou Y, Xiang F, Ni C, et al. Travel-associated outbreak of COVID-19 in a departmental store, Wenzhou, China. *J Infect Dev Ctries* **2022**; 16:752–8.
36. Zobrist S, Oliveira-Silva M, Vieira AM, et al. Screening for SARS-CoV-2 in close contacts of individuals with confirmed infection: performance and operational considerations. *J Infect Dis* **2022**; 226:2118–28.
37. McLean HQ, Grijalva CG, Hanson KE, et al. Household transmission and clinical features of SARS-CoV-2 infections. *Pediatrics* **2022**; 149:e2021054178.
38. Prunas O, Warren JL, Crawford FW, et al. Vaccination with BNT162b2 reduces transmission of SARS-CoV-2 to household contacts in Israel. *Science* **2022**; 375: 1151–4.
39. Donnelly MAP, Chuey MR, Soto R, et al. Household transmission of SARS-CoV-2 Alpha variant - United States, 2021. *Clin Infect Dis* **2022**; 75: e122–32.
40. Allen H, Tessier E, Turner C, et al. Comparative transmission of SARS-CoV-2 Omicron (B.1.1.529) and Delta (B.1.617.2) variants and the impact of vaccination: National Cohort Study, England. *medRxiv* 2022.02.15.22271001 [Preprint]. February 17, 2022. Available at: <https://doi.org/10.1101/2022.02.15.22271001>. Accessed August 1, 2022.
41. Wu J, Huang Y, Tu C, et al. Household transmission of SARS-CoV-2, Zhuhai, China, 2020. *Clin Infect Dis* **2020**; 71:2099–108.
42. Sun WW, Ling F, Pan JR, et al. Epidemiological characteristics of COVID-19 family clustering in Zhejiang province [in Chinese]. *Zhonghua Yu Fang Yi Xue Za Zhi* **2020**; 54:625–9.
43. Böhmer MM, Buchholz U, Corman VM, et al. Investigation of a COVID-19 outbreak in Germany resulting from a single travel-associated primary case: a case series. *Lancet Infect Dis* **2020**; 20:920–8.
44. Dong XC, Li JM, Bai JY, et al. Epidemiological characteristics of confirmed COVID-19 cases in Tianjin [in Chinese]. *Zhonghua Liu Xing Bing Xue Za Zhi* **2020**; 41:638–41.
45. Hua CZ, Miao ZP, Zheng JS, et al. Epidemiological features and viral shedding in children with SARS-CoV-2 infection. *J Med Virol* **2020**; 92:2804–12.
46. Chen Y, Wang AH, Yi B, et al. Epidemiological characteristics of infection in COVID-19 close contacts in Ningbo City [in Chinese]. *Zhonghua Liu Xing Bing Xue Za Zhi* **2020**; 41:667–71.
47. Xin H, Jiang F, Xue A, et al. Risk factors associated with occurrence of COVID-19 among household persons exposed to patients with confirmed COVID-19 in Qingdao municipal, China. *Transbound Emerg Dis* **2021**; 68: 782–8.
48. Wu Y, Song S, Kao Q, Kong Q, Sun Z, Wang B. Risk of SARS-CoV-2 infection among contacts of individuals with COVID-19 in Hangzhou, China. *Public Health* **2020**; 185:57–9.
49. Hu P, Ma M, Jing Q, et al. Retrospective study identifies infection related risk factors in close contacts during COVID-19 epidemic. *Int J Infect Dis* **2021**; 103:395–401.
50. Jing QL, Liu MJ, Zhang ZB, et al. Household secondary attack rate of COVID-19 and associated determinants in Guangzhou, China: a retrospective cohort study. *Lancet Infect Dis* **2020**; 20:1141–50.
51. Zhang W, Cheng W, Luo L, et al. Secondary transmission of coronavirus disease from presymptomatic persons, China. *Emerg Infect Dis* **2020**; 26:1924–6.
52. Singanayagam A, Hakki S, Dunning J, et al. Community transmission and viral load kinetics of the SARS-CoV-2 Delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study. *Lancet Infect Dis* **2022**; 22:183–95.
53. Cheng HY, Jian SW, Liu DP, Ng TC, Huang WT, Lin HH. Contact tracing assessment of COVID-19 transmission dynamics in Taiwan and risk at different exposure periods before and after symptom onset. *JAMA Intern Med* **2020**; 180:1156–63.
54. Ng OT, Koh V, Chiew CJ, et al. Impact of Delta variant and vaccination on SARS-CoV-2 secondary attack rate among household close contacts. *Lancet Reg Health West Pac* **2021**; 17:100299.
55. Kim J, Choe YJ, Lee J, et al. Role of children in household transmission of COVID-19. *Arch Dis Child* **2021**; 106:709–11.
56. Tak P, Rohilla J. COVID-19 contact tracing in a tertiary care hospital: a retrospective chart review. *Infect Dis Model* **2021**; 6:1–4.
57. Patel A, Charani E, Ariyanayagam D, et al. New-onset anosmia and ageusia in adult patients diagnosed with SARS-CoV-2 infection. *Clin Microbiol Infect* **2020**; 26:1236–41.
58. Boscolo-Rizzo P, Borsetto D, Spinato G, et al. New onset of loss of smell or taste in household contacts of home-isolated SARS-CoV-2-positive subjects. *Eur Arch Otorhinolaryngol* **2020**; 277:2637–40.
59. Rosenberg ES, Dufort EM, Blog DS, et al. COVID-19 testing, epidemic features, hospital outcomes, and household prevalence, New York state March 2020. *Clin Infect Dis* **2020**; 71:1953–9.
60. Trunfio M, Longo BM, Alladio F, et al. On the SARS-CoV-2 “variational hypothesis”: no association between viral load of index cases and COVID-19 severity of secondary cases. *Front Microbiol* **2021**; 12:646679.
61. Dattner I, Goldberg Y, Katriel G, et al. The role of children in the spread of COVID-19: using household data from Bnei Brak, Israel, to estimate the relative susceptibility and infectivity of children. *PLoS Comput Biol* **2021**; 17:e1008559.
62. Carazo S, Laliberté D, Villeneuve J, et al. Characterization and evolution of infection control practices among severe acute respiratory coronavirus virus 2 (SARS-CoV-2)-infected healthcare workers in acute-care hospitals and long-term care facilities in Québec, Canada, spring 2020. *Infect Control Hosp Epidemiol* **2022**; 43:481–9.
63. Bender JK, Brandl M, Höhle M, Buchholz U, Zeitmann N. Analysis of asymptomatic and presymptomatic transmission in SARS-CoV-2 outbreak, Germany, 2020. *Emerg Infect Dis* **2021**; 27:1159–63.
64. Lewis NM, Chu VT, Ye D, et al. Household transmission of severe acute respiratory syndrome coronavirus-2 in the United States. *Clin Infect Dis* **2021**; 73: 1805–13.
65. van der Hoek W, Backer JA, Bodewes R, et al. The role of children in the transmission of SARS-CoV-2 [in Chinese]. *Ned Tijdschr Geneesk* **2020**; 164:D5140.
66. Dawson P, Rabold EM, Laws RL, et al. Loss of taste and smell as distinguishing symptoms of coronavirus disease 2019. *Clin Infect Dis* **2021**; 72:682–5.
67. Wang Y, Tian H, Zhang L, et al. Reduction of secondary transmission of SARS-CoV-2 in households by face mask use, disinfection and social distancing: a cohort study in Beijing, China. *BMJ Glob Health* **2020**; 5:e002794.
68. Seto J, Aoki Y, Komabayashi K, et al. Epidemiology of coronavirus disease 2019 in Yamagata prefecture, Japan, January–May 2020: the importance of retrospective contact tracing. *Jpn J Infect Dis* **2021**; 74:522–9.
69. Han T. Outbreak investigation: transmission of COVID-19 started from a spa facility in a local community in Korea. *Epidemiol Health* **2020**; 42:e2020056.
70. Miyahara R, Tsuchiya N, Yasuda I, et al. Familial clusters of coronavirus disease in 10 prefectures, Japan, February–May 2020. *Emerg Infect Dis* **2021**; 27:915–8.
71. Bae S, Kim H, Jung TY, et al. Epidemiological characteristics of COVID-19 outbreak at fitness centers in Cheonan, Korea. *J Korean Med Sci* **2020**; 35:e288.
72. Doung-Ngern P, Suphanchaimat R, Panjangampathana A, et al. Case-control study of use of personal protective measures and risk for SARS-CoV 2 infection, Thailand. *Emerg Infect Dis* **2020**; 26:2607–16.
73. Pett J, McAleavey P, McGurnaghan P, et al. Epidemiology of COVID-19 in Northern Ireland, 26 February 2020–26 April 2020. *Epidemiol Infect* **2021**; 149:e36.
74. Wilkinson K, Chen X, Shaw S. Secondary attack rate of COVID-19 in household contacts in the Winnipeg Health Region, Canada. *Can J Public Health* **2021**; 112: 12–6.
75. Fateh-Moghadam P, Battisti L, Molinaro S, et al. Contact tracing during phase I of the COVID-19 pandemic in the province of Trento, Italy: key findings and recommendations. *medRxiv* 2020.07.16.20127357 [Preprint]. July 29, 2020.

- Available at: <https://doi.org/10.1101/2020.07.16.20127357>. Accessed June 20, 2022.
76. Kuba Y, Shingaki A, Nidaira M, et al. Characteristics of household transmission of COVID-19 during its outbreak in Okinawa, Japan from February to May 2020. *Jpn J Infect Dis* **2021**; 74:579–83.
 77. Phiriyasart F, Chantutanon S, Salaeh F, et al. Outbreak investigation of coronavirus disease (COVID-19) among Islamic missionaries in Southern Thailand, April 2020. *Outbreak Surveill Investig Res J* **2020**; 13:48–54.
 78. Arnedo-Pena A, Sabater-Vida S, Meseguer-Ferrer N, et al. COVID-19 secondary attack rate and risk factors in household contacts in Castellon (Spain): preliminary report. *Enfermedades Emergentes* **2020**; 19:64–70.
 79. Malheiro R, Figueiredo AL, Magalhães JP, et al. Effectiveness of contact tracing and quarantine on reducing COVID-19 transmission: a retrospective cohort study. *Public Health* **2020**; 189:54–9.
 80. Chaw L, Koh WC, Jamaludin SA, Naing L, Alikhan MF, Wong J. Analysis of SARS-CoV-2 transmission in different settings, Brunei. *Emerg Infect Dis* **2020**; 26:2598–606.
 81. Metlay JP, Haas JS, Soltoff AE, Armstrong KA. Household transmission of SARS-CoV-2. *JAMA Netw Open* **2021**; 4:e210304.
 82. Son H, Lee H, Lee M, et al. Epidemiological characteristics of and containment measures for COVID-19 in Busan, Korea. *Epidemiol Health* **2020**; 42:e2020035.
 83. Yung CF, Kam KQ, Chong CY, et al. Household transmission of severe acute respiratory syndrome coronavirus 2 from adults to children. *J Pediatr* **2020**; 225:249–51.
 84. Lee M, Eun Y, Park K, Heo J, Son H. Follow-up investigation of asymptomatic COVID-19 cases at diagnosis in Busan, Korea. *Epidemiol Health* **2020**; 42:e2020046.
 85. Draper AD, Dempsey KE, Boyd RH, et al. The first 2 months of COVID-19 contact tracing in the Northern Territory of Australia, March–April 2020. *Commun Dis Intell* (2018) **2020**; 44.
 86. Grijalva CG, Rolfes MA, Zhu Y, et al. Transmission of SARS-COV-2 infections in households - Tennessee and Wisconsin, April–September 2020. *MMWR Morb Mortal Wkly Rep* **2020**; 69:1631–4.
 87. Vallès X, Roure S, Valerio L, et al. SARS-CoV-2 contact tracing among disadvantaged populations during epidemic intervals should be a priority strategy: results from a pilot experiment in Barcelona. *Public Health* **2021**; 195:132–4.
 88. Koureas M, Speletas M, Bogogiannidou Z, et al. Transmission dynamics of SARS-CoV-2 during an outbreak in a Roma community in Thessaly, Greece—control measures and lessons learned. *Int J Environ Res Public Health* **2021**; 18:2878.
 89. Jashaninejad R, Doosti-Irani A, Karami M, Keramat F, Mirzaei M. Transmission of COVID-19 and its determinants among close contacts of COVID-19 patients running title. *J Res Health Sci* **2021**; 21:e00514.
 90. Demko ZO, Antar AAR, Blair PW, et al. Clustering of SARS-CoV-2 infections in households of patients diagnosed in the outpatient setting in Baltimore, Maryland. *Open Forum Infect Dis* **2021**; 8:ofab121. doi: [10.1093/ofid/ofab121](https://doi.org/10.1093/ofid/ofab121).
 91. Teherani MF, Kao CM, Camacho-Gonzalez A, et al. Burden of illness in households with severe acute respiratory syndrome coronavirus 2-infected children. *J Pediatric Infect Dis Soc* **2020**; 9:613–6.
 92. Areekal B, Vijayan SM, Suseela MS. Risk factors, epidemiological and clinical outcome of close contacts of covid-19 cases in a tertiary hospital in Southern India. *J Clin Diagn Res* **2021**; 15:34–7.
 93. Lyngse FP, Kirkeby C, Halasa T, et al. Nationwide study on SARS-CoV-2 transmission within households from lockdown to reopening, Denmark, 27 February 2020 to 1 August 2020. *Euro Surveill* **2022**; 27:2001800.
 94. Charbonnier L, Roupère-Serzec J, Caseris M, et al. Contribution of serological rapid diagnostic tests to the strategy of contact tracing in households following SARS-CoV-2 infection diagnosis in children. *Front Pediatr* **2021**; 9:638502.
 95. Islam SS, Noman AS. Transmission dynamics and contact tracing assessment of COVID-19 in Chattogram, Bangladesh and potential risk of close contacts at different exposure settings. SSRN ssn.3677863 [Preprint], October 12, 2020. Available at: <https://dx.doi.org/10.2139/ssrn.3677863>. Accessed June 25, 2022.
 96. Adamik B, Bawiec M, Bezborodov V, et al. Bounds on the total number of SARS-CoV-2 infections: the link between severeness rate, household attack rate and the number of undetected cases. ResearchGate RG.2.2.30750.77124 [Preprint]. July 2020. Available at: <http://dx.doi.org/10.13140/RG.2.2.30750.77124>. Accessed June 10, 2022.
 97. Laxminarayan R, Wahl B, Dudala SR, et al. Epidemiology and transmission dynamics of COVID-19 in two Indian states. *Science* **2020**; 370:691–7.
 98. Shah K, Kandre Y, Mavalankar D. Secondary attack rate in household contacts of COVID-19 paediatric index cases: a study from Western India. *J Public Health (Oxf)* **2021**; 43:243–5.
 99. Semakula M, Niragire F, Umutohi A, et al. The secondary transmission pattern of COVID-19 based on contact tracing in Rwanda. *BMJ Glob Health* **2021**; 6:e004885.
 100. Goma MR, El Rifay AS, Shehata M, et al. Incidence, household transmission, and neutralizing antibody seroprevalence of coronavirus disease 2019 in Egypt: results of a community-based cohort. *PLoS Pathog* **2021**; 17:e1009413.
 101. Tanaka ML, Ruiz CJM, Malhotra S, et al. Urban household transmission of SARS-CoV-2 during periods of high and low community transmission. SSRN ssn.3801730 [Preprint]. March 10, 2021. Available at: <http://dx.doi.org/10.2139/ssrn.3801730>. Accessed June 20, 2022.
 102. Cerami C, Popkin-Hall ZR, Rapp T, et al. Household Transmission of Severe Acute Respiratory Syndrome Coronavirus 2 in the United States: Living Density, Viral Load, and Disproportionate Impact on Communities of Color. *Clin Infect Dis* **2022**; 74:1776–85.
 103. Hsu CY, Wang JT, Huang KC, Fan AC, Yeh YP, Chen SL. Household transmission but without the community-acquired outbreak of COVID-19 in Taiwan. *J Formos Med Assoc* **2021**; 120(Suppl 1):S38–45.
 104. Sundar V, Bhaskar E. Low secondary transmission rates of SARS-CoV-2 infection among contacts of construction laborers at open air environment. *Germes* **2021**; 11:128–31.
 105. Loenenbach A, Markus I, Lehfeld AS, et al. SARS-CoV-2 variant B.1.1.7 susceptibility and infectiousness of children and adults deduced from investigations of childcare centre outbreaks, Germany, 2021. *Euro Surveill* **2021**; 26:2100433.
 106. Reid MJA, Prado P, Brosnan H, et al. Assessing testing strategies and duration of quarantine in contact tracing for SARS-CoV-2: a retrospective study of San Francisco's COVID-19 contact tracing program, June–August 2020. *Open Forum Infect Dis* **2021**; 8. doi: [10.1093/ofid/ofab171](https://doi.org/10.1093/ofid/ofab171).
 107. Peng J, Liu J, Mann SA, et al. Estimation of secondary household attack rates for emergent spike L452R severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants detected by genomic surveillance at a community-based testing site in San Francisco. *Clin Infect Dis* **2022**; 74:32–9.
 108. Lyngse FP, Mølbak K, Skov RL, et al. Increased transmissibility of SARS-CoV-2 lineage B.1.1.7 by age and viral load. *Nat Commun* **2021**; 12:7251.
 109. Telle K, Jørgensen SB, Hart R, Greve-Isdahl M, Kacelnik O. Secondary attack rates of COVID-19 in Norwegian families: a nation-wide register-based study. *Eur J Epidemiol* **2021**; 36:741–8.
 110. Awang H, Yaacob EL, Syed Aluawi SN, et al. A case-control study of determinants for COVID-19 infection based on contact tracing in Dungun district, Terengganu state of Malaysia. *Infect Dis (Lond)* **2021**; 53:222–5.
 111. Tibebu S, Brown K A., Daneman N, Paul LA, Buchan SA. Household secondary attack rate of COVID-19 by household size and index case characteristics. medRxiv 2021.02.23.21252287 [Preprint]. February 25, 2021. Available at: <https://doi.org/10.1101/2021.02.23.21252287>. Accessed June 20, 2022.
 112. Akaishi T, Kushimoto S, Katori Y, et al. COVID-19 transmission in group living environments and households. *Sci Rep* **2021**; 11:11616.
 113. Harris RJ, Hall JA, Zaidi A, Andrews NJ, Dunbar JK, Dabrera G. Effect of vaccination on household transmission of SARS-CoV-2 in England. *N Engl J Med* **2021**; 385:759–60.
 114. Afonso ET, Marques SM, Costa LDC, et al. Secondary household transmission of SARS-CoV-2 among children and adolescents: clinical and epidemiological aspects. *Pediatr Pulmonol* **2022**; 57:162–75.
 115. Baker JM, Nakayama JY, O'Hegarty M, et al. SARS-CoV-2 B.1.1.529 (Omicron) variant transmission within households - four U.S. jurisdictions, November 2021–February 2022. *MMWR Morb Mortal Wkly Rep* **2022**; 71:341–6.
 116. Bistaraki A, Roussos S, Tsiodras S, Sypsa V. Age-dependent effects on infectivity and susceptibility to SARS-CoV-2 infection: results from nationwide contact tracing data in Greece. *Infect Dis (Lond)* **2022**; 54:186–95.
 117. Burke RM, Calderwood L, Killerby ME, et al. Patterns of virus exposure and presumed household transmission among persons with coronavirus disease, United States, January–April 2020. *Emerg Infect Dis* **2021**; 27:2323–32.
 118. Calvani M, Cantiello G, Cavani M, et al. Reasons for SARS-CoV-2 infection in children and their role in the transmission of infection according to age: a case-control study. *Ital J Pediatr* **2021**; 47:193.
 119. Cheng VC, Siu GK, Wong SC, et al. Complementation of contact tracing by mass testing for successful containment of beta COVID-19 variant (SARS-CoV-2 VOC B.1.351) epidemic in Hong Kong. *Lancet Reg Health West Pac* **2021**; 17:100281.
 120. Chu VT, Yousaf AR, Chang K, et al. Household transmission of SARS-CoV-2 from children and adolescents. *N Engl J Med* **2021**; 385:954–6.
 121. Clifford S, Waigh P, Hackman J, et al. Effectiveness of BNT162b2 and ChAdOx1 against SARS-CoV-2 household transmission: a prospective cohort study in England. medRxiv 2021:2021.11.24.21266401.

122. Cohen C, Kleynhans J, von Gottberg A, et al. SARS-CoV-2 incidence, transmission, and reinfection in a rural and an urban setting: results of the PHIRST-C cohort study, South Africa, 2020-21. *Lancet Infect Dis* **2022**; 22:821–34.
123. de Gier B, Andeweg S, Backer JA, et al. Vaccine effectiveness against SARS-CoV-2 transmission to household contacts during dominance of Delta variant (B.1.617.2), the Netherlands, August to September 2021. *Euro Surveill* **2021**; 26:2100977.
124. de Gier B, Andeweg S, Joosten R, et al. Vaccine effectiveness against SARS-CoV-2 transmission and infections among household and other close contacts of confirmed cases, the Netherlands, February to May 2021. *Euro Surveill* **2021**; 26:2100640.
125. Del Águila-Mejía J, Wallmann R, Calvo-Montes J, Rodríguez-Lozano J, Valle-Madrado T, Aginagalde-Llorente A. Secondary attack rate, transmission and incubation periods, and serial interval of SARS-CoV-2 Omicron variant, Spain. *Emerg Infect Dis* **2022**; 28:1224–8.
126. Dougherty K, Mannell M, Naqvi O, Matson D, Stone J. SARS-CoV-2 B.1.617.2 (Delta) variant COVID-19 outbreak associated with a gymnastics facility - Oklahoma, April-May 2021. *MMWR Morb Mortal Wkly Rep* **2021**; 70:1004–7.
127. Dub T, Nohynek H, Hagberg L, et al. High secondary attack rate and persistence of SARS-CoV-2 antibodies in household transmission study participants, Finland 2020. *Front Med (Lausanne)* **2022**; 9:876532.
128. Friedman-Klabanoff DJ, Fitzpatrick MC, Deming ME, et al. Risk of SARS-CoV-2 acquisition is associated with individual exposure but not community-level transmission. *J Infect Dis* **2022**; 226:225–35.
129. Gazit S, Mizrahi B, Kalkstein N, et al. BNT162b2 mRNA vaccine effectiveness given confirmed exposure: analysis of household members of COVID-19 patients. *Clin Infect Dis* **2021**; 75:e734–40.
130. Ge Y, Martinez L, Sun S, et al. COVID-19 transmission dynamics among close contacts of index patients with COVID-19: a population-based cohort study in Zhejiang province, China. *JAMA Intern Med* **2021**; 181:1343–50.
131. Gorgels KMF, Alphen LB, van der Veer BMJW, et al. Increased transmissibility of SARS-CoV-2 Alpha variant (B.1.1.7) in children: three large primary school outbreaks revealed by whole genome sequencing in the Netherlands. *BMC Infect Dis* **2021**; 22:713.
132. Hwang H, Lim JS, Song SA, et al. Transmission dynamics of the Delta variant of SARS-CoV-2 infections in South Korea. *J Infect Dis* **2022**; 225:793–9.
133. Jagdale G, Parande M, Borle P, et al. Secondary attack rate among the contacts of COVID-19 patients at the beginning of the pandemic in Pune City of Western Maharashtra, India. *J Commun Dis* **2021**; 53:51–9.
134. Jalali N, Brustad HK, Frigessi A, et al. Increased household transmission and immune escape of the SARS-CoV-2 Omicron variant compared to the Delta variant: evidence from Norwegian contact tracing and vaccination data. *Nat Commun* **2022**; 13:5706.
135. Kang M, Xin H, Yuan J, et al. Transmission dynamics and epidemiological characteristics of SARS-CoV-2 Delta variant infections in Guangdong, China, May to June 2021. *Euro Surveill* **2022**; 27:2100815.
136. Karumanagoundar K, Raju M, Ponnaiah M, et al. Secondary attack rate of COVID-19 among contacts and risk factors, Tamil Nadu, March-May 2020: a retrospective cohort study. *BMJ Open* **2021**; 11:e051491.
137. Layan M, Gilboa M, Gonen T, et al. Impact of BNT162b2 vaccination and isolation on SARS-CoV-2 transmission in Israeli households: an observational study. *Am J Epidemiol* **2022**; 191:1224–34.
138. Li Y, Liu J, Yang Z, et al. Transmission of severe acute respiratory syndrome coronavirus 2 to close contacts, China, January-February 2020. *Emerg Infect Dis* **2021**; 27:2288–93.
139. Liu PY, Gragnani CM, Timmerman J, et al. Pediatric household transmission of severe acute respiratory coronavirus-2 infection—Los Angeles County, December 2020 to February 2021. *Pediatr Infect Dis J* **2021**; 40:e379–e81.
140. Loss J, Wurm J, Varnaccia G, et al. Transmission of SARS-CoV-2 among children and staff in German daycare centers: results from the COALA study. *Epidemiol Infect* **2022**; 150:e141.
141. Lyngse FP, Kirkeby CT, Denwood M, et al. Household transmission of SARS-CoV-2 Omicron variant of concern subvariants BA.1 and BA.2 in Denmark. *Nat Commun*. **2022**; 13:5760.
142. Lyngse FP, Mølbak K, Denwood M, et al. Effect of vaccination on household transmission of SARS-CoV-2 Delta variant of concern. *Nat Commun* **2022**; 13:3764.
143. Lyngse FP, Mortensen LH, Denwood MJ, et al. SARS-CoV-2 Omicron VOC transmission in Danish households. *Nat Commun* **2022**; 13:5573.
144. Ma X, Wu K, Li Y, et al. Contact tracing period and epidemiological characteristics of an outbreak of the SARS-CoV-2 Delta variant in Guangzhou. *Int J Infect Dis* **2022**; 117:18–23.
145. Martinez DA, Klein EY, Parent C, et al. Latino household transmission of severe acute respiratory syndrome coronavirus 2. *Clin Infect Dis* **2022**; 74:1675–7.
146. Martínez-Baz I, Trobajo-Sanmartín C, Miqueleiz A, et al. Product-specific COVID-19 vaccine effectiveness against secondary infection in close contacts, Navarre, Spain, April to August 2021. *Euro Surveill* **2021**; 26:2100894.
147. Meyer ED, Sandfort M, Bender J, et al. Two doses of the mRNA BNT162b2 vaccine reduce severe outcomes, viral load and secondary attack rate: evidence from a SARS-CoV-2 alpha outbreak in a nursing home in Germany, January-March 2021. medRxiv 2021.09.13.21262519 [Preprint]. September 23, 2021. Available at: <https://doi.org/10.1101/2021.09.13.21262519>. Accessed June 20, 2022.
148. Li F, Li YY, Liu MJ, et al. Household transmission of SARS-CoV-2 and risk factors for susceptibility and infectivity in Wuhan: a retrospective observational study. *Lancet Infect Dis* **2021**; 21:617–28.
149. Wang X, Pan Y, Zhang D, et al. Basic epidemiological parameter values from data of real-world in mega-cities: the characteristics of COVID-19 in Beijing, China. *BMC Infect Dis* **2020**; 20:526.
150. Park SY, Kim YM, Yi S, et al. Coronavirus disease outbreak in call center, South Korea. *Emerg Infect Dis* **2020**; 26:1666–70.
151. Liu T, Liang W, Zhong H, et al. Risk factors associated with COVID-19 infection: a retrospective cohort study based on contacts tracing. *Emerg Microbes Infect* **2020**; 9:1546–53.
152. Zhang JZ, Zhou P, Han DB, et al. Investigation on a cluster epidemic of COVID-19 in a supermarket in Liaocheng, Shandong province [in Chinese]. *Zhonghua Liu Xing Bing Xue Za Zhi* **2020**; 41:2024–8.
153. Park YJ, Choe YJ, Park O, et al. Contact tracing during coronavirus disease outbreak, South Korea, 2020. *Emerg Infect Dis* **2020**; 26:2465–8.
154. Bi Q, Wu Y, Mei S, et al. Epidemiology and transmission of COVID-19 in 391 cases and 1286 of their close contacts in Shenzhen, China: a retrospective cohort study. *Lancet Infect Dis* **2020**; 20:911–9.
155. Burke RM, Midgley CM, Dratch A, et al. Active monitoring of persons exposed to patients with confirmed COVID-19 - United States, January-February 2020. *MMWR Morb Mortal Wkly Rep* **2020**; 69:245–6.
156. Luo L, Liu D, Liao X, et al. Contact settings and risk for transmission in 3410 close contacts of patients with COVID-19 in Guangzhou, China: a prospective cohort study. *Ann Intern Med* **2020**; 173:879–87.
157. Hu S, Wang W, Wang Y, et al. Infectivity, susceptibility, and risk factors associated with SARS-CoV-2 transmission under intensive contact tracing in Hunan, China. *Nat Commun* **2021**; 12:1533.
158. Zhuang YL, Zhang YT, Li M, et al. Analysis on the cluster epidemic of coronavirus disease 2019 in Guangdong province [in Chinese]. *Zhonghua Yu Fang Yi Xue Za Zhi* **2020**; 54:720–5.
159. Wu P, Liu F, Chang Z, et al. Assessing asymptomatic, presymptomatic, and symptomatic transmission risk of severe acute respiratory syndrome coronavirus 2. *Clin Infect Dis* **2021**; 73:e1314–20.
160. Petherick A, Goldszmidt R, Andrade EB, et al. A worldwide assessment of changes in adherence to COVID-19 protective behaviours and hypothesized pandemic fatigue. *Nat Hum Behav* **2021**; 5:1145–60.
161. Chan HF, Skali A, Savage DA, Stadelmann D, Torgler B. Risk attitudes and human mobility during the COVID-19 pandemic. *Sci Rep* **2020**; 10:19931.
162. Hitchings MDT, Dean NE, García-Carreras B, et al. The usefulness of the test-positive proportion of severe acute respiratory syndrome coronavirus 2 as a surveillance tool. *Am J Epidemiol* **2021**; 190:1396–405.
163. Wu SL, Mertens AN, Crider YS, et al. Substantial underestimation of SARS-CoV-2 infection in the United States. *Nat Commun* **2020**; 11:4507.
164. Yi S, Kim JM, Choe YJ, et al. SARS-CoV-2 Delta variant breakthrough infection and onward secondary transmission in household. *J Korean Med Sci* **2022**; 37:e12.
165. Lopez Bernal J, Panagiotopoulos N, Byers C, et al. Transmission dynamics of COVID-19 in household and community settings in the United Kingdom, January to March 2020. *Euro Surveill* **2022**; 27:2001551.
166. Meena MS, Priya S, Thirukumaran R, Gowrilakshmi M, Essakiraja K, Madhumitha MS. Factors influencing the acquisition of COVID infection among high-risk contacts of COVID-19 patients in Madurai district—a case control study. *J Family Med Prim Care* **2022**; 11:182–9.
167. Miller E, Waight PA, Andrews NJ, et al. Transmission of SARS-CoV-2 in the household setting: a prospective cohort study in children and adults in England. *J Infect* **2021**; 83:483–9.
168. Manatu Hauora Ministry of Health. COVID-19 variants update. December 3, 2021. Available at: <https://www.health.govt.nz/system/files/documents/pages/22-november-2021-variants-update-summary.pdf>. Accessed August 1, 2022.
169. Montecucco A, Dini G, Rahmani A, et al. Investigating SARS-CoV-2 transmission among co-workers in a University of Northern Italy during COVID-19 pandemic: an observational study. *Med Lav* **2021**; 112:429–35.
170. Musa S, Kissling E, Valenciano M, et al. Household transmission of SARS-CoV-2: a prospective observational study in Bosnia and Herzegovina, August-December 2020. *Int J Infect Dis* **2021**; 112:352–61.

171. Ng DC, Tan KK, Chin L, et al. Risk factors associated with household transmission of SARS-CoV-2 in Negeri Sembilan, Malaysia. *J Paediatr Child Health* **2022**; 58:769–73.
172. Ogata T, Irie F, Ogawa E, et al. Secondary attack rate among non-spousal household contacts of coronavirus disease 2019 in Tsuchiura, Japan, August 2020–February 2021. *Int J Environ Res Public Health* **2021**; 18:8921.
173. Rajmohan P, Jose P, Thodi J, et al. Dynamics of transmission of COVID-19 cases and household contacts: a prospective cohort study. *J Acute Dis* **2021**; 10:162–8.
174. Ratovoson R, Razafimahatratra R, Randriamanantsoa L, et al. Household transmission of COVID-19 among the earliest cases in Antananarivo, Madagascar. *Influenza Other Respir Viruses* **2022**; 16:48–55.
175. Remón-Berrade M, Guillen-Aguinaga S, Sarrate-Adot I, et al. Risk of secondary household transmission of COVID-19 from health care workers in a hospital in Spain. *Epidemiologia* **2022**; 3:1–10.
176. Sachdev DD, Chew Ng R, Sankaran M, et al. Contact tracing outcomes among household contacts of fully vaccinated COVID-19 patients - San Francisco, California, January 29–July 2, 2021. *Clin Infect Dis* **2021**; 75:e267–75.
177. Smith-Jeffcoat SE, Pomeroy MA, Sleweon S, et al. Multistate outbreak of SARS-CoV-2 B.1.1.529 (Omicron) variant infections among persons in a social network attending a convention - New York City, November 18–December 20, 2021. *MMWR Morb Mortal Wkly Rep* **2022**; 71:238–42.
178. Song JS, Lee J, Kim M, et al. Serial intervals and household transmission of SARS-CoV-2 Omicron variant, South Korea, 2021. *Emerg Infect Dis* **2022**; 28:756–9.
179. Soriano-Arandes A, Gatell A, Serrano P, et al. Household severe acute respiratory syndrome coronavirus 2 transmission and children: a network prospective study. *Clin Infect Dis* **2021**; 73:e1261–9.
180. Tanaka H, Hirayama A, Nagai H, et al. Increased transmissibility of the SARS-CoV-2 Alpha variant in a Japanese population. *Int J Environ Res Public Health* **2021**; 18:7752.
181. ur Rehman S, Qaisrani MI, Abbasi SH, et al. COVID-19 outbreak in Islamabad resulting from a travel-associated primary case: a case series. *J Global Biosecur* **2022**; 20:488.
182. Watanapokasin N, Siripongboonsitti T, Ungtrakul T, et al. Transmissibility of SARS-CoV-2 variants as a secondary attack in Thai households: a retrospective study. *IJID Reg* **2021**; 1:1–2.
183. Campbell F, Archer B, Laurenson-Schafer H, et al. Increased transmissibility and global spread of SARS-CoV-2 variants of concern as at June 2021. *Euro Surveill* **2021**; 26:2100509.
184. Araf Y, Akter F, Tang YD, et al. Omicron variant of SARS-CoV-2: genomics, transmissibility, and responses to current COVID-19 vaccines. *J Med Virol* **2022**; 94:1825–32.
185. Public Health Ontario. Phylogenetic analysis of SARS-CoV-2 in Ontario (Nextstrain interface hosted at Public Health Ontario). **2021**. Available at: https://www.publichealthontario.ca/-/media/data-files/technical-notes-nextstrain.pdf?la=en&sc_lang=en&hash=7E40DF3950E479DA558A7D51D5BF8E4A. Accessed August 1, 2022.